Atrium Therapeutics, Inc. (RNA) stock
RNANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$6.48+0.05 (+0.78%)
Close on Nov 17, 2026Market cap $110.85MP/E –Yield –
Atrium Therapeutics EV/EBITDA
EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.
No ev/ebitda figures for Atrium Therapeutics
Atrium Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?